Clinical & Scientific

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

A new 750-patient clinical trial is underway to provide definitive evidence for advanced thrombectomy, potentially changing how deadly blood clots are treated.

In a strategic play, VIVUS is slashing the price of its oral obesity drug QSIVA, challenging the dominance of costly new injectables like Wegovy.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

A new alliance between Discovery Life Sciences and Mindpeak aims to solve inconsistent biomarker interpretation, a critical bottleneck in cancer drug development.

Tempest Therapeutics raises up to $6M in a critical financing deal to advance its CAR-T pipeline, balancing promising clinical data with financial pressures.

The Chuck Noll Foundation's first symposium reveals pioneering research on women's health and brain banking, cementing Pittsburgh's role in the fight against concussions.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

Endevica Bio launches Kalohexis, a new biotech aiming to disrupt the obesity market with a drug that resets the body's 'metabolic thermostat'.

Red Light Holland is deploying advanced AI from Kala Bio to accelerate its botanical psilocybin program, signaling a new high-tech era for mental health.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.

A new partnership seeks to conquer C. difficile, a deadly hospital infection that has stumped pharma giants, by advancing a novel dual-action vaccine.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

Pierre Fabre's Avène brand is using AI to sextuple its clinical trial size for a new acne treatment, signaling a new era for dermo-cosmetic research.